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ABSTRACT
ENHANCED RENAL SYMPATHETIC
AND CARDIOVASCULAR RESPONSES
TO SUBSTANCE P IN HYPERTENSION
by
Gregory W. Lindsay
Blood pressure, heart rate, and renal sympathetic nerve
responses were measured in 9-13 week old male spontaneously
hypertensive rats (SHR) and compared to those in age and
sex-matched Wistar-Kyoto (WHY) rats following intravenous
injection of the neuropeptide substance P (SP), the
nicotinic stimulant 1,l-dimethyl-4-phenylpiperazinium
(DMPP), and the adrenoceptor stimulant norepinephrine (NE).
Charles River Sprague-Dawley (CD) rats were used in some
studies to develop methodologies. Measurements were made in
control rats and also following sinoaortic denervation,
pithing, ganglion blockade, or adrenoceptor blockade.
Responses were evaluated in order to determine if
ganglion stimulation by SP was enhanced in SHR compared to
WHY rats and if this enhancement was selective for SP or
would also be exhibited to DMPP. NE was used to evaluate
adrenergic sensitivity and to confirm the success of
baroreceptor denervations,
SHR exhibited greater intrinsic sympathetic tone than
WKY rats before and following ganglion blockade. Ganglion
stimulation by SP and DMPP was only fully revealed following
elimination of baroreceptor input. Results indicated that
SP stimulates sympathetic ganglia to increase renal
sympathetic nerve activity, heart rate and blood pressure in
CD, SHR and WKY rats. This increase was enhanced in SHR
compared to WKY rats in the absence of a similar enhancement
of responses to DMPP. The action of SP to cause
vasodilation was attenuated in SHR versus WKY rats which may
augment its action as a pressor agent in SHR.
In conclusion, increases in blood pressure, heart rate
and renal sympathetic nerve activity were selectively
increased to SP in SHR versus WKY rats. This enhanced
action of SP may contribute to the elevation of basal and/or
evoked sympathetic discharge observed in this model of
hypertension.
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CHAPTER 1
Introduction

Substance £
Substance P (SP) is one of the oldest known peptide
neurotransmitters (Otsuka and Konishi, 1983).

It was

originally isolated from equine brain and intestine and
noted to have a hypotensive action that was not blocked by
atropine when injected intravenously into anesthetized
rabbits (von Euler and Gaddum, 1931).

The proposal that SP

may act as a neurotransmitter or neuromodulator came
somewhat later (Lembeck, 1953).

The peptide is now known to

be distributed throughout the central nervous system (Cooper
et al., 1981) and is also found in several locations within
the peripheral nervous system where it has a variety of
functions (Schultzberg, 1983).
The presence of SP in the peripheral sympathetic
nervous system was first shown by Pernow (1953).

SP was

later localized to nerve terminals surrounding principal
cells of sympathetic ganglia by Hdkfelt and colleagues
(1977).

Several lines of evidence now indicate that SP is

released in sympathetic ganglia where it acts to enhance
neurotransmission by evoking a late-onset slow-excitatory
postsynaptic potential (EPSP) (Otsuka and Yoshioka, 1993).
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Substance P in Hypertension
An enhancement of neurotransmission through sympathetic
ganglia has been proposed to contribute to the development
and/or maintenance of hypertension in spontaneously
hypertensive rats (SHR) (Magee and Schofield, 1992).

Since

sympathetic ganglia of SHR have been shown to exhibit
increased immunoreactivity to SP compared to normotensive
Wistar-Kyoto (WKY) rats (Gurusinghe and Bell, 1989), SP may
be involved in the pathogenesis of hypertension in this
model.

This proposal was tested in the current study by

evaluation of blood pressure, heart rate and renal
sympathetic nerve activity (RSNA) following intravenous
injection of SP in SHR and WKY rats.

The rationale for

employing this methodology is based on studies which have
shown that when given intravenously in sufficient doses (>1.0
nmol/kg), SP has an action to increase blood pressure and
heart rate which overcomes its hypotensive effect.

These

actions were prevented by adrenoceptor blockade or depletion
of catecholamines with reserpine but not by ganglion nicotinic
receptor blockade or pithing, therefore they appear to be due
to stimulation of sympathetic ganglia (Hancock, 1992).
The hypothesis of the present study is that increases in
blood pressure, heart rate, and RSNA observed after
intravenous injection of SP will be greater in SHR than in WKY
rats.

Additionally, the increased responsiveness of SHR is

proposed to be selective for SP and not be exhibited to other
ganglion stimulants.

Overview of Hypertension
Circulatory diseases account for approximately one half
of all deaths of people 50 years of age and older living in
western countries, with the prevalence of hypertension in
this population being about 55% (Kaplan, 1990; Whelton and
Klag, 1989).

Of particular significance is that the level

of blood pressure serves as an accurate risk predictor for
other circulatory disorders with high rates of mortality
including coronary artery disease, cerebrovascular disease,
and congestive heart failure.

As a result, there has been

abundant research directed at ascertaining possible causes
and potential treatments for hypertension.

Although current

theories attempting to describe the pathogenesis remain
varied and fraught with controversy, some factors have been
identified which are likely to be involved in the etiology
(Folkow, 1982).
Blood pressure is ultimately determined by the product
of cardiac output and peripheral vascular resistance.
Hypertension must therefore be the result of an increase in
one or both of these factors.

Studies indicate that both an

enhanced cardiac output and increased vasomotor tone
contribute to the pathogenesis of hypertension, but somewhat
differently.

Early hypertension is often characterized by

an elevation in cardiac output with normal or even decreased
resistance, while an increase in peripheral vascular
resistance is generally considered to be the primary
hemodynamic abnormality in established hypertension (Folkow,
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1982).

Both of these variables are controlled via

Interaction of a variety of physiologic mechanisms.

Among

the most prominent and powerful of these is the sympathetic
nervous system.

Importance of the Sympathetic Nervous System
The role of the sympathetic nervous system in
initiating rapid cardiovascular adjustments to acute changes
in the environment is well known.

Following sympathetic

stimulation, neurally released norepinephrine produces
sustained arteriolar constriction in several vascular beds
thus increasing peripheral vascular resistance.

Sympathetic

output to the heart and adrenal medulla causes both heart
rate and stroke volume to increase, enhancing cardiac
output.

Sympathetic stimulation of the kidneys causes

sodium and water retention with increased renin-angiotensin
and aldosterone release, enhancing both cardiac output and
vascular resistance.

In this way, blood pressure is

maintained or altered appropriately in order to accommodate
the immediate and short term needs of an individual.
The role of the sympathetic nervous system in causing
more or less permanent circulatory changes is less clear.
Because the sympathetic nervous system regulates blood
pressure via feedback mechanisms (i.e. input affects output
and vice-versa), permanent changes in the physiological
state of the heart and/or vasculature can result in chronic
changes in sympathetic tone.

In the same way, a persistent
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change in the output of sympathetic nerves can cause
adaptive alteration of the cardiovascular system.

Lastly,

the neuronal circuitry may be disrupted, requiring more or
less input for the same amount of output.

In fact, each of

these types of changes have been observed in hypertension
(Abboud, 1982).

It is therefore not surprising that the

observation of enhanced basal and evoked sympathetic
discharge in both human and experimental hypertension has
received considerable attention (Folkow, 1989).

Structural Remodeling
Cardiovascular adaptations following chronic elevation
of systemic arterial pressure occur in proportion to the
level of hypertension and without regard to the cause.
Rapid structural alterations including hypertrophy of the
heart and precapillary vessels are exhibited following
sustained increases in intraluminal pressure (Folkow, 1978).
This results in an increase in the ratio between wall
thickness and lumen diameter that leads to the development
of higher pressures in response to stimulation, an effect
which has been proposed to be responsible for maintenance of
chronic hypertension (Folkow, 1987).

Decreased

responsiveness to depressor substances is also observed,
particularly those responses mediated by the vascular
endothelium (Luscher et al., 1992).
However, cardiovascular remodeling may also occur
independent of hypertension per se.

There is considerable

evidence that sympathetic nerves have a trophic influence on
vascular smooth muscles cells (Abel and Hermsmeyer, 1981}.
An increase in the vascular wall:lumen ratio has been
observed in early hypertension which is dependent on the
presence of sympathetic nerves (Hart et al., 1980),

This is

due to an increase in the mass of the medial layer of the
vessel wall resulting from a hyperplasia and hypertrophy of
vascular smooth muscle cells.

This proliferation of smooth

muscle cells can be demonstrated in cell culture upon
addition of norepinephrine (Blaes and Boissel, 1983).

In

addition, surgical or chemical denervation of sympathetic
nerves prevents vascular hyperplastic changes in
experimental hypertension (Head, 1989).

Thus, the

sympathetic nervous system appears to mediate both acute and
chronic increases in vascular resistance, and may be
involved in the maintenance of chronic hypertension by this
mechanism.
In addition to contributing to maintenance of chronic
high blood pressure, increased sympathetic outflow is
probably also an important factor during the developmental
phase of hypertension.

Sympathetic hyperresponsiveness to

environmental factors such as emotional stress or increased
dietary salt intake is often exhibited in individuals
genetically predisposed to hypertension (Folkow, 1989).

In

particular, sympathoadrenal responsiveness is often elevated
(de Champlain et al., 1989), resulting in increased release
of epinephrine and perhaps contributing to the increase in

cardiac output often observed in early hypertension.

A

possible explanation for this hyperresponsiveness is an
alteration in nervous control of sympathetic tone.

Neurogenic Control
Sympathetic neurons involved in regulation of the
cardiovascular system may be classified on the basis of
function as those associated with the origination of
sympathetic discharge, those involved only in modulation of
sympathetic tone, and those which integrate and deliver
sympathetic discharge to target organs.

A.

Generation of Sympathetic outflow

Sympathetic discharge to the cardiovascular system is
believed to be generated by spontaneous activity present
within cells of the rostral ventrolateral medulla (RVLM).
Specifically, epinephrine-containing cells of the Cl
(catecholamine) area of the RVLM appear to provide tonic
excitatory input to sympathetic preganglionic neurons in the
intermediolateral (IML) cell column of the spinal cord (Reis
et al., 1988).

This hypothesis is supported by the fact

that destruction or inhibition of Cl neurons markedly
depresses sympathetic tone resulting in hypotension and
bradycardia,

m

addition, increases in arterial pressure

are observed following stimulation of medullary sites
containing descending Cl axons (Calaresu and Yardley, 1988).
In conflict with this hypothesis is the observation
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that application of epinephrine to the IML cell column
consistently inhibits firing of preganglionic nerves, an
effect which is blocked by e2-adrenoceptor antagonists
(Guyenet and stornetta, 1982).

This suggests that

bulbospinal epinephrine pathways are not excitatory but may
be Bympathoinhibitory in nature.

In addition, while ct2

antagonists appear to block all the effects of epinephrine
on sympathetic preganglionic neurons, they fail to prevent
excitation of preganglionic cells elicited by stimulation of
pressor sites in the Cl area of the RVIM (McCall, 1990).
Therefore, although the generation of sympathetic tone is
likely to be mediated by cells within or in close proximity
to Cl neurons, they do not appear to utilize epinephrine as
their sole transmitter.

Other neurotransmitters of the RVLM

which may play a role in maintaining vasomotor tone include
glutamate, 5-hydroxytryptamine (5-HT), and the neuropeptide
substance P (SP) (McCall, 1990).

B.

Modulation of Sympathetic Tone

Basal sympathetic tone is modified by several inputs at
virtually all levels.

This myriad of inputs allows for

exceptional selective control of sympathetic discharge.

It

also creates numerous opportunities for potential
disturbances in neuroregulation and great difficulty in
pinpointing the origin of these disturbances.

Supraspinal

structures known to influence sympathetic tone include the
nucleus tractus solitarius (NTS), caudal ventrolateral

medulla, circumventricular organs, basal forebraln, dorsal
raphe nuclei, parabrachial nucleus, Al and A5 noradrenergic
cell groups, several areas within the hypothalamus, and the
cerebral cortex (McCall, 1990).

Because abundant relays

originating from several nuclei occur in the NTS, it serves
as a kind of central processor, integrating input from the
many other brain stem and forebrain nuclei and relaying it
to the RVLM.
Neurons in the Cl area of the RVLM receive dense input
from the NTS, which is in turn highly innervated by sensory
fibers from arterial baroreceptors and other cardiopulmonary
afferents (Brody, 1986).

Baroreceptors are specialized

nerve endings found in the carotid body and aortic arch
which increase their rate of firing in response to
distension of the arterial wall.

Changes in blood pressure

alter the strain on these fibers thus influencing their
discharge rate.

Increased baroreceptor activity excites

neurons in the NTS which causes inhibition of
sympathoexcitatory neurons in the R V m .

This neuronal

negative feedback helps to buffer against changes in
arterial pressure.

Alterations in the reflex may therefore

contribute to chronic changes in arterial pressure.

The

observation that vascular compliance is decreased in
hypertension lead to the hypothesis by some researchers that
reduced baroreceptor stretch might cause chronic elevation
of sympathetic tone.

This was subsequently thought to be

unlikely when it was determined that baroreceptors reset to

new thresholds following sustained Increases In arterial
pressure (McCubbln et al., 1956).

However, since

baroreceptors resist changes In blood pressure, they may
play a role in the maintenance of hypertension.

Resetting

of the reflex to a higher pressure threshold may actively
oppose a subsequent return to normal blood pressure levels.

C.

Delivery of Sympathetic Outflow

Centrally generated sympathetic discharge is carried by
a serially linked two-neuron pathway to effector cells in
the periphery# constituting the final phase in sympathetic
nervous control of the cardiovascular system.

Nervous

activity in descending tracts is transferred to
preganglionic neurons in the IML cell column of the spinal
cord which relay their output through sympathetic ganglia to
postganglionic neurons innervating the target organs.
However, this pathway is more than a simple relay circuit
for transfer of information from higher centers to the
periphery.

Integration of information from a multitude of

sensory and supraspinal inputs occurs, thus ensuring highly
differentiated sympathetic output to multiple target cells.

sympathetic Preganglionic Neurons
A. Inputs
Preganglionic sympathetic neurons receive inputs from
supraspinal neurons as well as visceral and somatic spinal
afferents.

Since visceral and somatic sensory fibers also
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influence descending input from supraspinal cell groups,
afferent modulation of sympathetic tone at the level of the
preganglionic neuron is extensive.

This markedly influences

not only the level of activity in sympathetic preganglionic
neurons, but also their pattern of discharge.

B.

Synchronized Discharge

Ongoing activity in sympathetic nerves is usually
synchronized in a periodic fashion either with pulse
pressure or respiration, depending on the target organ
(Laskey and Polosa, 1988).

This rhythmicity is directly

related to the strength of inhibitory influences exerted on
sympathetic discharge by peripheral cardiopulmonary and
baroreceptor inputs.

These sensory fibers affect

sympathetic tone via central pathways involving the NTS.
However, it should be noted that rhythmic modulation of
sympathetic activity has also been observed in baroreceptor
denervated animals which is not synchronized with pulse
pressure or respiration.

This rhythmicity has been

attributed to activity of supraspinal oscillators (Kenney et
al., 1990; Barman et al, 1992).

When arterial baroreceptors

are intact these oscillators are thought to become entrained
to the rhythm of afferent nerve activity.

Whatever the

case, afferent influences on sympathetic preganglionic nerve
activity are considerable.

C. Electrophysiology
Four types of synaptic potentials have been identified
in sympathetic preganglionic neurons in vitro.

These are: a

fast and a slow excitatory postsynaptic potential (EPSP) and
a fast and a slow inhibitory postsynaptic potential (IPSP).
Not all of these necessarily occur in every preganglionic
cell (Simmons, 1985).
Stimulation of dorsal roots (sensory input to the spinal
cord) elicits an excitatory synaptic potential in
preganglionic neurons of long but variable length (2-10 ms)
which is capable of producing an action potential (Tsunoo et
al., 1982).
EPSP.

This type of potential is classified as a fast

Because of the varying length, it probably represents

events mediated by one or more interneurons.

The response

has been attributed to stimulation of N-methyl-D-aspartate
(NMDA) receptors due to similarities in the evoked
depolarizations and the fact that NMDA receptor antagonists
block fast EPSP's following dorsal root stimulation (Dun et
al., 1992).

A non-NMDA mediated fast EPSP of shorter

duration has also been noted.

The transmitter(s) mediating

this response remains unknown.
Fast IPSP's are noted in about 30% of preganglionic
neurons following stimulation of the dorsal roots.

This is

blocked by the glycine antagonist strychnine, but not the
gamma aminobutyric acid (GABA) antagonist bicuculline (Dun et
al., 1992).

Thus, inhibitory glycine interneurons probably

mediate fast IPSP's in sympathetic preganglionic neurons.
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Studies using antagonists and/or putative transmitters
indicate that the transmitter responsible for slow EPSP's in
preganglionic neurons is heterogeneous.

Some possible

transmitters mediating this response include norepinephrine,
epinephrine, substance p, 5-HT, glutamate, and vasopressin
(Dun et al., 1991).

Slow IPSP's are blocked by

02

-

adrenoceptor antagonists, and thus are likely to be mediated
by catecholamines (Nishi, 1990).

Sympathetic Ganglia
A. Overview
It has become clear that preganglionic signals are not
conveyed to postganglionic neurons by simple excitatory
monosynaptic transmission.

Neurotransmission in sympathetic

ganglia involves a variety of synaptic events whereby
central and peripheral inputs are integrated.

Excluding

presynaptic modulation of transmitter release occurring at
the adrenergic nerve terminal, this constitutes the final
point for adjustment of sympathetic discharge.
The neural elements which participate in ganglionic
transmission are: preganglionic nerve terminals, post
ganglionic neurons (which have their cell bodies in
sympathetic ganglia), ganglionic interneurons (strongly
immuno-fluorescent i.e. SIF cells), axons from post
ganglionic cells in neighboring ganglia, and collaterals
from visceral sensory fibers.

Glial cells may also be

present in some sympathetic ganglia participating in
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modulation of transmission.
Classically, preganglionic nerve fibers projecting to
sympathetic ganglia exert effects on postganglionic neurons
via release of the neurotransmitter acetylcholine, which
stimulates postjunctional nicotinic receptors.

Recently,

immunoreactivity to the peptides calcitonin gene related
peptide (CGRP) and vasoactive intestinal peptide (VIP) has
been demonstrated in preganglionic neurons projecting to the
superior cervical ganglia of the rat (Yamamoto et al., 1989;
Baldwin et al., 1991).

These peptides may function either

as neurotransmitters or as modulators of transmission in
sympathetic ganglia.

B. Prejunctional Modulation
Prejunctional modulation of transmitter release occurs
in sympathetic ganglia via several types of receptors.
Activation of muscarinic acetylcholine receptors of the M2
type found on the axon terminal has been shown to inhibit
synaptic transmission.

Adrenoceptors of the a2 type, 5-HTi

receptors, histamine H2 receptors, and opiate receptors also
appear to decrease transmitter release from the
preganglionic nerve terminal.

On the other hand, activation

of B-adrenoceptors, histamine H2 receptors, VIP receptors,
or angiotensin II receptors found on the preganglionic nerve
terminal results in an enhancement of ganglionic
neurotransmission.

Inhibitory effects on neurotransmission

due to the actions of GABA and prostaglandin E2 have also
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been noted, however their mechanisms of action are unclear
(Kuba and Minota, 1986).

C. Postsynaptic Responses
At least three types of excitatory receptors are found
postsynaptically on sympathetic ganglion cells: nicotinic,
muscarinic, and peptidergic.

Stimulation of these receptors

results in the generation of a fast EPSP, slow EPSP, and
late slow EPSP, respectively (Elfvin et al., 1993).
Nicotinic and muscarinic receptor stimulation is due to
acetylcholine released from the preganglionic nerve
terminal.

It has recently been determined that peptidergic

stimulation results from the release of the neuropeptide SP
from axon collaterals of primary sensory neurons of the
dorsal root ganglia (Otsuka and Konishi, 1983).

Similar

ganglion stimulatory actions have also been attributed to
other peptides such as calcitonin gene-related peptide
(CGRP), which occurs with SP in some sensory fibers (Gibbins
et al., 1985), but these effects are less well established.
Circulating peptides with stimulatory effects on ganglionic
transmission include angiotensin II and bradykinin, which
may be important in hormonal modulation of sympathetic tone.
Inhibitory potentials in mammalian sympathetic ganglia
are less well understood, although a slow IPSP can be
demonstrated following nicotinic receptor blockade which may
be due either to stimulation of muscarinic receptors,
catecholamine receptors, or both (Elfvin et al., 1993).
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Muscarinic receptor mediated slow IPSPs are difficult to
study due to superimposition of the muscarinic slow EPSP.
Catecholamines in sympathetic ganglia might be released from
SIF cells or from axons of neighboring ganglia.
Amplitudes of fast EPSPs are usually large enough to
generate an action potential at the postsynaptic site,
therefore nicotinic transmission is a primary synaptic
pathway in sympathetic ganglia (Kuba and Minota et al.,
1986).

However, visceral afferent control of sympathetic

tone also appears to be significant.

A delayed onset, long-

lasting depolarization is produced following application of
SP to sympathetic ganglion neurons (Dun and Karczmar, 1979)
which has been shown to be capable of generating action
potentials (Konishi and Otsuka, 1985).

In addition,

sympathetic activity is enhanced following intravenous
injection of SP resulting in increases in blood pressure and
heart rate (Hancock et al., in preparation),

since SP-

containing sensory nerve terminals innervate both the
peripheral vasculature and sympathetic ganglia, this may
provide a mechanism for peripheral reflex regulation of
vasomotor tone.

The Spontaneously Hypertensive Rat
Studies directed at defining the role of the
sympathetic nervous system in hypertension have often
utilized the SHR, a genetic model in which hypertension
develops gradually with age.

As in human essential
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hypertension, this increase in blood pressure is very
closely associated with increased activity of the
sympathetic nervous system (Judy et al., 1976).

Studies in

the SHR utilize the inbred normotensive WKY rat as a
control.

WKY rats are similar in lineage to the SHR but do

not develop hypertension (Louis and Howes, 1990).
Several points within both the central and peripheral
sympathetic nervous system have been identified as possible
locations for disturbances which affect regulation of
sympathetic tone in the SHR (Ekas et al., 1981).

Some

factors which may potentially operate to increase
postganglionic sympathetic tone include: an enhanced action
of angiotensin at circumventricular organs (Brody et al.,
1991), attenuation of baroreceptor sensitivity (Nosaka and
Wang, 1972), hypernoradrenergic innervation (Head, 1991),
altered membrane handling of sodium (Folkow and Ely, 1987),
and differences in modulation of sympathetic tone by
sympathetic ganglia (Magee and Schofield, 1992).

It is

difficult to point to one causative factor since changes
occurring peripherally can affect central control of
sympathetic tone, and vice versa.
Of particular interest is the fact that neonatal
depletion of sensory peptides by treatment with capsaicin
prevents the development of hypertension in SHR (Scott and
Pang, 1982).

Since capsaicin selectively depletes sensory

peptides, this indicates that sensory nerves play a role in
the development of hypertension in the SHR.

It is unknown
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if capsaicin treatment is accompanied by a decrease in
sympathetic tone.

However, this may be the case since the

sensory peptide SP is known to significantly enhance
neurotransmission in sympathetic ganglia (Konishi and
Otsuka, 1985).

In addition, observations that

immunoreactivity to SP is increased in sympathetic ganglia
of SHR (Gususinghe and Bell, 1989) support the idea that
sensory nerves are involved in elevating sympathetic tone in
SHR, perhaps contributing to the development and/or
maintenance of hypertension.

If sensory peptides such as

substance p have an increased action in the SHR to enhance
neurotransmission in sympathetic ganglia, this may
contribute to hypertension by elevating blood pressure more
in SHR than WKY rats.

This idea was tested in the current

study by comparing cardiovascular and renal sympathetic
nerve responses of SHR versus WKY rats following intravenous
injection of substance P.

Responses to the ganglion

nicotinic stimulant DMPP and the adrenoceptor stimulant
norepinephrine were also evaluated in order to determine if
changes in responsiveness were selective for SP.

CHAPTER 2
Materials and Methods

This project was divided into six sets of experiments
based on parameters measured, treatments, techniques, and
the strain of rat that was used.

Charles River Sprague-

Dawley (CD) rats were used to develop the methodology for
recording from the renal sympathetic nerve and to
investigate the effects of various treatments such as
pithing and baroreceptor denervation on responses to
ganglion stimulation.

SHR and WKY rats were used to

determine if blood pressure, heart rate and renal nerve
responses to sympathetic ganglion stimulation were enhanced
in the SHR versus WKY.

Though not shown in each instance,

baseline blood pressures were significantly higher in all
groups of SHR compared to WKY rats.

Source of Animals
Male 8-10 week old SHR and WKY rats were obtained from
Charles River Labs (Research Triangle Park, NC) and allowed
to acclimatize for 1-3 weeks prior to each experiment.

Male

CD rats were taken from an active breeding colony maintained
by the Department of Laboratory Animal Resources (breeders
were from Charles River Laboratories) at the Quillen College
of Medicine (Johnson City, TN).
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Source of Drugs
Substance P was purchased from Bachem Inc., Torrance,
CA.

DMPP [1,l-dimethyl-4-phenylpiperazinium iodide] was

from ICN Pharmaceuticals, Plainview, NY.
[(-)-arterenol bitartrate],

Norepinephrine

(±)-propranolol, and gallamine

triethiodide were from Sigma Chemical Co., St. Louis, HO.
Chlorisondamine chloride [Ecolid] was from CIBA
Pharmaceutical Co., Summit, NJ.

Phenoxybenzamine HC1 was

from Smith Kline & French Labs, Philadelphia, PA.

Statistical Methods
Blood pressure, heart rate and renal sympathetic nerve
responses to each dose of each drug as well as basal levels
of blood pressure and nerve activity are compared between
strains (SHR vs. WKY) and between groups (control vs.
sinoaortic denervated or control vs. ganglion blocked) by a
one-way analysis of variance (F-test).

Significant

differences are assigned at a probability level of less than
0.05 (p<0,05) and indicated in figures by an asterisk (*).

General Procedures
Rats were anesthetized with an initial intraperitoneal
injection of 55-65 mg/kg sodium pentobarbital (65 mg/ml).
Supplemental intravenous injections of 10-20 mg/kg were
given periodically during the experiment to maintain the
level of anesthesia.

The trachea was cannulated to
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facilitate respiration.

With the aid of a stereozoom

microscope, polyethylene (PE) tubing containing heparinized
saline was then inserted approximately 5 mm into the left
jugular vein (PE 20, l unit heparin/ml) and right femoral
artery (PE 50, 100 units heparin/ml) for administration of
drugs and measurement of arterial pressure, respectively.
An initial dose of 50 units heparin sodium in 0.5 ml of
saline was given to flush the arterial catheter and prevent
clotting during the experiment.

Subsequent drug injections

were given in volumes of approximately 50 ^1, depending on
rat weight.

Up to three concentration-response curves to

different drugs were constructed in each rat, depending on
the stability of blood pressure and RSNA.

The order in

which different drugs were given was selected randomly, with
drug injections being given stepwise from the lowest to the
highest concentration.

Blood pressure, heart rate and RSNA

were allowed to return to normal and stabilize after each
drug injection.

The venous catheter was flushed with 100

pi

of saline prior to the first injection of each drug.

Isolation of the Renal Nerve
In experiments where renal nerve activity was
monitored, the rat was next placed on its right side and the
left kidney exposed through a 3 cm retroperitoneal flank
incision just below the diaphragm.

The kidney was retracted

ventrally and secured, with care taken to avoid disruption
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of renal blood flow.

With the aid of a fiber-optic lamp and

under magnification, the perirenal fat and connective tissue
were carefully dissected to expose a renal nerve.

This

nerve is found lying near the junction of the abdominal
aorta and renal artery in CD rats or about 1 cm
rostroventral to this in SHR and WKY rats.

The nerve was

covered with heavy mineral oil to prevent drying and
carefully freed from surrounding tissue for a length of 5-10
mm

Bipolar silver electrodes (diameter 0.008") were placed

under the nerve, raised gradually, and secured in a position
of stable contact.

Responses were measured only from

preparations in which nerve recordings exhibited
baroreceptor sensitive pulse-synchronous activity.

Artificial Respiration
Spontaneously breathing rats were used during the first
three studies (i.e. the effect of SP on blood pressure and
heart rate, stimulation of RSNA by SP, and effect of
ganglion blockade on responses to SP in SHR and WKY rats).
All rats in other studies were paralyzed and placed on
artificial respiration at the start of the experiment.

This

was necessary in pithed and baroreceptor denervated rats
because of an inability of the rat to ventilate itself.
Control and adrenoceptor-blocked rats were also artificially
ventilated for appropriate group to group comparison of
responses.

Neuromuscular blockade was effected by
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intravenous injection of 50 /unol/kg gallamine triethiodide,
a concentration which produces neuromuscular blockade
without affecting ganglionic neurotransmission (experimental
observations).

Immediately following cessation of

respiration, rats were ventilated at a rate of 70-80/min.
with a humidified 100% oxygen/room air mixture using a Model
683 Harvard Rodent Ventilator.

Tidal volume was adjusted

for dead space, rat weight and respiratory rate in the range
of 1.5-2.5 ml based on documented respiratory parameters
provided with the ventilator,

Baroreceptor Denervation
Bilateral sinoaortic denervation was performed by
exposing the carotid sinus and both vagi for a length of
approximately 2 cm

The aortic depressor nerve was

identified and cut, followed by removal of the superior
cervical ganglion.

Next, using a very fine forceps, the

carotid sinus was stripped of all adventitia from
approximately 1 cm above to l cm below the bifurcation of
the internal carotid and external carotid arteries.

This

area was painted with a solution of 10% phenol in saline and
allowed to sit for 5 minutes.

Both vagi were then cut, and

artificial respiration initiated.

Sinoaortic denervation

was deemed successful if no decrease in renal sympathetic
nerve activity was observed following injection of 10-20
nmol/kg norepinephrine.
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Pithlna
Rats were pithed by insertion of a 2 mm diameter steel
rod through a small incision into the spinal column at the
level of the first cervical vertebrae.

The rod was advanced

through the entire length of the spinal cord, then the
direction reversed for destruction of the brain stem.
Artificial respiration was initiated immediately following
this maneuver*

Measurement of Blood Pressure and Heart Rate
A. Equipment
Systemic arterial pressure was measured by a Statham
pressure transducer and amplified by a Gould Universal
Amplifier, Model 13-4615-58.

Heart rate was determined from

the frequency of arterial pressure pulses by a Gould Biotach
Amplifier, Model 13-G4615-66.

Signals were relayed to a

Gould Brush model 2400 pen writing recorder for analysis.

B. Data Analysis
Drug-induced changes in heart rate were calculated by
subtracting pre-drug values from the maximum heart rate
observed following drug injection.

Mean arterial pressure

was approximated as two-thirds of diastolic pressure plus
one-third of systolic pressure.

Values were measured at the

point of maximum change in diastolic pressure.
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Two different methods were used to measure blood
pressure responses to substance P.

In the first set of

experiments, mean arterial pressure was measured at two
points following injection of SP (figure 1).

The first

measurement was taken at the point of maximum decrease in
pressure immediately following injection of sp (point #1).
Mean arterial pressure at this point was subtracted from the
pre-drug value thus giving a negative number.

The second

measurement was taken at the apex of the transient increase
in pressure observed following high doses of SP (point #2).
Point #1 is subtracted from point #2 thus giving zero or a
positive number.

This method, which takes into account both

the vasodilatory and sympathoexcitatory effects of SP was
used in analysis of blood pressure responses to SP in the
first set of experiments.

In the remainder of the

experiments, mean arterial pressure was measured at point #2
(occurring about 20 seconds after SP injection) and compared
to the pre-drug value.

Although this method does not

distinguish between vasodilatory and sympathoexcitatory
effects of SP, it was felt that it contained less
variability and when combined with measurements of renal
nerve activity would provide adequate information.
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Figure 1: Blood pressure responses to substance P. The first
method used to assess responses measured two points.
The
vasodilatory response was evaluated by measuring mean arterial
pressure at point #1 and comparing it to the pre-drug value.
The sympathoexcitatory response was evaluated by measuring
mean arterial pressure at point #2 and comparing it to point
#1. A second method used to measure the blood pressure
response measured only a single value by comparing point #2 to
the pre-drug value.
Renal Sympathetic Nerve Recordings
A. Equipment
Renal nerve recordings were performed inside a 2.5x4x2*
cast iron cage (open at the front) for isolation from
extraneous electrical noise.

Bipolar nerve signals were

amplified approximately 20,000 times in three stages using a
Grass P15 AC Preamplifier (bandpass 3-1000 Hz, gain=10), a
Gould Isolated Preamplifier, Model 13-5407-58 (gain»20), and
a Gould Universal Amplifier, Model 13-4615-58 (bandpass 31000 Hz, gain=100).

Nerve signals were also relayed

directly from the Grass preamplifier to a Tektronix Type

561B Oscilloscope for visualization.

The Grass and Gould

preamplifiers were placed inside the iron cage to provide
high impedance (200 and 1000 megohm, respectively)
differential amplification (with common mode rejection) of
nerve signals close to the source.

A grounding circuit was

created by wire connections from the cage to five locations:
the rat, the Grass preamplifier, the Gould preamplifier, the
rodent ventilator, and earth.

The rat was also connected to

ground on the Grass preamplifier.

Raw renal sympathetic

nerve activity was transferred from the Gould Universal
Amplifier to a Gould Integrator Amplifier, Model 13-4616-70
(time constant « 1 second) and also (in the last set of
experiments only) to a R.C. Electronics ISC-16 Analog to
Digital converter card (sample rate = 2000 Hz) installed in
a Zenith Data Systems Z-station 433Dh computer.

Hardcopy

output from the computer is via a Hewlett-Packard Deskjet
500 printer (figure 2).
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Figure 2: Equipment configuration for bipolar differential
recording of renal sympathetic nerve activity.
Raw renal
nerve activity is output to an oscilloscope for visualization,
to an integrator for continuous hardcopy monitoring and to a
computer for spectral analysis. Arrows indicate signal wires,
lines indicate ground wires.

B.

Data Analysis

Two methods were used for measurement of renal
sympathetic nerve activity: integration and power spectral
analysis.

Spectral analysis was available only in the last

set of experiments (effect of baroreceptor denervation on
responses in SHR and WKY rats)♦

Previous experiments used
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integration as a means for measuring neural activity.
Spectral analysis was used when available instead of
integration because of advantages in data retrieval by
computer and because of the ability of spectral analysis to
analyze the character of nerve activity in addition to
integrating its amplitude.

1.

Integration

Integration of nerve activity is a common method used
to measure neural activity in multifiber nerve recordings
(Hopp et al., 1986), consisting simply of a periodic
summation of the signal amplitude.

Integration of bipolar

differential recordings is necessarily preceded by full-wave
rectification to avoid cancellation of the signal due to its
equivalent positive and negative composition.

Full-wave

rectification is accomplished within the circuitry of the
integrator.

Integrated signals must be reset periodically

to maintain values within an acceptable range.

This is also

provided for by the integrator, which allows for either
internal or external reset timing.

In the current study,

integrated nerve activity was reset by an internal timer at
a frequency of 1 Hz

In essence, this sets the resolution of

the integrator to allow for measurement of changes in nerve
activity occurring over an interval of

tl second.

Of the four sets of experiments in which nerve activity
was monitored, the integration method was used in the first
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three to quantitate nerve discharges.

In these studies,

values for relative nerve activity minus background noise
were calculated by measuring the height in mm of individual
integration spikes, converting to arbitrary units and then
squaring this value.

Arbitrary scaling was set to 5

units/cm in the first two studies and 20 units/cm in the
third, with 5 cm constituting a full scale deflection.
Resulting relative nerve activity values were proportional
to (volts/second)2, a measure of multifiber nerve activity
which exhibits linearity with respect to both frequency and
amplitude changes (Dulli et al., 1984).

Background noise

was taken as the minimum value of relative activity observed
following baroreceptor activation or pithing.

2.

Spectral Analysis

Power spectral analysis of nerve recordings is a method
which has recently received much attention, due in part to
the increased availability of high-speed computers necessary
for the analog to digital conversion and processing
involved.

The technique has advantages over other methods

(such as integration) in that in addition to measuring
signal amplitude, spectral analysis provides information
about the nature of a signal's temporal structure.

This

data is useful since information contained in nerve
discharges may be encoded in both frequency and amplitude
components.
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Spectral analysis mathematically reduces bioelectric
phenomena into frequency components of defined amplitude
(figure 3).

Thus, the signal may be expressed graphically

with frequency usually represented on the x axis versus
voltage on the y axis.

This representation of a neurogram

is termed the autospectrum.

Power spectral analysis differs

from simple spectral analysis in that amplitude is expressed
in units of volts2, as opposed to volts.

Theoretically, if

the autospectrum of a nerve signal is known, that signal can
be reconstructed exactly by reversing the mathematical
transform.

This mathematical transform is called the

Fourier Transform.

Several variants of the Fourier

Transform exist, each with different applications under
varying conditions.

Continuous Fourier Transforms assume

that the signal contains an infinite number of frequency
components and are therefore expressed as a line or curve in
the x-y domain.

Discrete Fourier Transforms assume a finite

number of frequency components, each separated by l/t Hz,
where t = the duration of the source signal in seconds, and
are expressed in a form similar to a histogram.

A type of

Discrete Fourier Transform which lends itself especially
well to analysis of digitized signals is the Fast Fourier
Transform (FFT) because it analyzes segments of data rather
than attempting to transform a continuous wave form (Glaser
and Ruchkin, 1976).

The FFT was used for analysis of renal

sympathetic nerve recordings in the current study.

32
Renal sympathetic nerve activity was stored in digital
format on a 200 megabyte fixed computer disk at a sampling
rate of 2000 Hz.

This data was analyzed by a FFT using the

R.C. Electronics Computerscope Enhanced Graphics Acquisition
and Analysis (EGAA) System software package.

Neurograms

were analyzed in 2 second segments, resulting in power
spectra with a resolution of 1/2 Hz.

Autospectrum exhibited

both low (3-8 Hz) and high (10-500 Hz) frequency components,
with most of the power being distributed between 100 and 200
Hz (figure 3).

The low frequency component corresponded to

the rate of synchronized nerve discharge.

This discharge

was observed to occur most often during the diastolic phase
of the cardiac cycle (figure 4).

Power was transferred to

the lower frequency component following rectification of the
signal (figure 5), therefore this technique is useful for
coherence analysis of synchronous nerve discharge.

However,

changes in the level of nerve activity were reflected as
increases or decreases in the total power contained in
autospectra of raw, unrectified neurograms, a measurement
which was more useful in the current study than coherence
analysis.

Therefore, effects of ganglion stimulation or

baroreceptor activation on renal nerve activity were
measured by calculating changes in total power (contained in
all frequencies) of the unrectified signal.
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Autospectrum of Efferent
Renal Nerve Activity
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Figure 3: Autospectral analysis of a bipolar renal sympathetic
nerve recording. Low frequency (approximately 5 Hz) and high
frequency (100-200 Hz) components are displayed.
The low
frequency component corresponds to the rate of synchronous
discharge.
Total power contained in all frequencies of the
autospectrum corresponds to relative nerve activity.
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Coherence of Arterial Pressure (AP) Pulse with
Efferent Renal Sympathetic Nerve Activity (RSNA)
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Figure 4: The temporal relationship of blood pressure and
efferent renal sympathetic nerve activity is shown.
Bursts
occur most often in synchrony with the diastolic phase of the
cardiac cycle.
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Figure 5: Autospectra1 analysis of a rectified bipolar renal
sympathetic nerve recording. Power is primarily distributed
to frequencies corresponding to the rate of synchronous
discharge (about 5 Hz).

CHAPTER 3
Results

The Effect of Substance P
on Blood Pressure and Heart Rate
Blood pressure and heart rate responses to intravenous
injection of

sp

(0.03-30 nmol/kg), DMPP (0.03-3.0 jimol/kg)

and NE (0.3-30 nmol/kg) were measured in 9-11 week old male
SHR (n=4) and WKY (n=5) rats.

Substance P increased heart

rate and caused biphasic changes in blood pressure
consisting of an initial decrease in pressure followed by a
dose-dependent rise in blood pressure (figures 6,7).

R esp on ses o f a Typical WKY Rat to Injection of
Low (0.3 nmol/kg) and High Dose (3 2 nmol/kg) S u b stan ce P

0 3 nod/kg
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Figure 6: Typical changes in heart rate and blood pressure
observed after injection of 0.3 and 32 nmol/kg substance P in
a WKY rat.
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R esponses of a Typical SHR to Injection of
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Figure 7: Typical changes in heart rate and blood pressure in an
SHR following injection of 0.3 and 32 nmol/kg substance P.
Maximal decreases in blood pressure occurred approximately
10 seconds after injection of SP.

At high doses,

this was

followed by an increase in pressure reaching its maximum after
about

20

seconds.

Doses

of

SP

greater

than

3.0

nmol/kg

increased pressure in SHR sufficiently to overcome the initial
decrease.

In contrast, this did not occur in WKY rats owing to

the fact that the secondary increase in blood pressure due to SP
was less than that observed in SHR (figure 8), while the initial
decrease in pressure was greater (figure 9).

Note; method #1

described on pages 25-26 was used to measure blood pressure
responses here.
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Increase (n Blood Pressure due to Substance P
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Figure 8: Magnitude of the secondary increase in mean arterial
pressure due to injection of substance P in SHR and WKY rats.
Increases in pressure to 0.1-30 nmol/kg SP were significantly
greater in SHR versus WKY rats, with the highest dose increasing
pressure by 48.3 ± 6.9 vs. 12.0 ± 3.3 mmHg, respectively.
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Figure 9: Maximum decrease in mean arterial pressure due to
substance P in SHR and WKY rats. Decreases in arterial pressure
following 0.1-3.0 nmol/kg SP were significantly greater in WKY
rats compared to SHR by an average of 13.7 mmHg.
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Tachycardia

occurred

following

SP

injection,

with

increases in heart rate being significantly greater in SHR
compared to WKY rats (figure 10).

The onset of this increase

in heart rate was slightly delayed compared to blood pressure
responses,

reaching a maximum approximately 30-50

seconds

after drug injection.
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Figure 10: Maximal increase in heart rate following injection
of substance P in SHR and WKY rats. Increases in heart rate
to 3.0-30 nmol/kg SP were statistically greater in SHR
compared to WKY rats, with the highest dose increasing rate by
90 ± 8 versus 21 ± 11 beats/min., respectively.
In contrast to the differences observed in responses to
SP, pressor and tachycardic effects of DMPP and NE were
similar in the two groups (figures 11-14).

Tachycardic

responses to NE were variable due to reflex bradycardia
which occurred in some rats.
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Figures 11 £ 12: Increase in mean arterial pressure and heart
rate due to the ganglion nicotinic agonist 1,1-dimethy1-4phenylpiperazinium (DMPP) in SHR and WHY rats. Responses were
similar between the two groups, with a statistical difference
being observed only in the tachycardic effect of 0.3 /raol/kg
DHPP.
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Figures 13 s 14: Increase in mean arterial pressure and heart
rate due to the adrenoceptor stimulant norepinephrine in SHR
and WKY rats.
Ho statistical differences were seen between
responses in the two groups.
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Stimulation of RSNA bv Substance P
The technique for recording renal sympathetic nerve
activity (RSNA) was developed in CD rats in order to provide
a direct measurement of the effect of SP on postganglionic
sympathetic nerve activity.

Following intravenous injection

of substance P (0.3-30 nmol/kg), a dose-dependent increase
in RSNA was observed (figure 15a).

This effect coincided

with increases in blood pressure and heart rate, supporting
the idea that pressor and tachycardic effects of SP result
from increases in sympathetic tone.

In addition, since

these effects were not eliminated by ganglion blockade with
20 pmol/kg chlorisondamine (figure 15b) or following
destruction of the spinal cord by pithing (figure 15c), they
are not due to an action on the central nervous system.
Injection of 0.05 ml of vehicle did not affect RSNA, blood
pressure or heart rate (figure 16).

These observations

support the idea that SP stimulates sympathetic ganglia
following high dose (£ 3.0 nmol/kg) intravenous injection.

GANGLION

PITHING

BLOCXAOE

Figure 15: Effect of 30 nmol/kg substance P on heart rate,
blood pressure, and renal sympathetic nerve activity (RSNA) in
CD rats.
Both raw and integrated RSNA are shown.
Control
responses are shown in panel A.
Panel B shows a typical
response
following ganglion blockade
(with 20
pmol/kg
chlorisondamine).
Panel
C shows the
response after
destruction of the central nervous system by pithing.
Drug
injections are indicated by an arrow above the blood pressure
tracing. Each panel depicts 75 seconds of data.
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m m m

Figure 16: The effect of injection of 50 fil vehicle (normal
saline) on blood pressure and RSNA in a CD rat* Injection is
indicated by an arrow above the blood pressure tracing,
A
small transient increase in blood pressure is observed which
has no significant effect on RSNA.
75 seconds of data are
shown.

Effect of Ganglion Blockade on
Responses to SP in SHR and WKY rats
Blood pressure, heart rate and RSNA responses to
intravenous injection of SP (0.3-30 nmol/kg) were measured
in 10-12 week old male SHR (n=9) and WKY (n=6) rats before
and following blockade of ganglion nicotinic receptors with
chlorisondamine (20 /xmol/kg).

Cardiovascular responses to

SP prior to ganglion blockade were similar to those observed
previously in SHR and WKY rats.

Biphasic blood pressure

responses were evaluated by measuring mean arterial pressure
approximately 20 seconds following injection of SP at the
point of maximal increase in pressure (refer to figure 1).
Differences in the blood pressure response to 1.0-30
nmol/kg SP were seen in SHR compared to WKY rats prior to
ganglion blockade, with 3.0-30 nmol/kg SP increasing
pressure above baseline only in SHR (figure 17).

These

differences were reduced after ganglion blockade, with
increases in pressure to 3.0-30 nmol/kg SP being exhibited
in both SHR and WKY rats (figure 18).

Note: this was likely

due to the fact that mean arterial pressure was reduced
following ganglion blockade, resulting in attenuation of
vasodilatory effects of SP.
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Change in MAP 20 sec Following Substance P
Injection in SHR and WKY rats
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Figure 17: The change in mean arterial pressure (HAP) 20
seconds after injection of substance P in SHR and WKY rats.

Change in MAP 20 sec Following i.v. Substance P
in SHR and WKY rats after Ganglion Blockade
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Figure 18: The change in mean arterial pressure (MAP) 20
seconds after injection of substance P in SHR and WKY rats
after ganglion blockade with 20 junol/kg chlorisondamine.
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The magnitude of intrinsic RSNA in SHR was nearly twice
that in WKY rats (154 ± 18 versus 80 ± 8.5, arbitrary units).
In addition, this ratio was maintained after ganglion
blockade with 20 jtmol/kg chlorisondamine (46 ± 8.5 versus 22
± 5.8 units, figure 19).

Relative nerve activity is measured

in arbitrary units proportional to (volts/second)2.

Renal Sympathetic Nerve Activity in SHR and WKY rats
Before and After Ganglion Blockade
I
154

t is

■

| Control
Ganglion Blockade

[chlorliondtmlne] * 20 umol/kg
• » p < 0.05 vs. SHR

a loo

8 0 t 8 .5

46 i 8.5
If
22 i 5.8

SHR

WKY

(n = 5 ,4 )

(n=5,5)

Figure 19: Relative renal sympathetic nerve activity (RSNA) in
SHR and WKY rats before and following ganglion blockade with
20 pmol/kg chlorisondamine. RSNA is significantly greater in
SHR compared to WKY rats both before and after ganglion
blockade.
SP enhanced RSNA in both SHR and WKY rats.

This

increase was preceded by a slight decrease in nerve activity
which was particularly apparent in SHR (figure 20).

This

inhibition of RSNA predominated over stimulatory effects of
SP at lower doses and attenuated the increase in RSNA
observed at high doses.

Perhaps due to this effect, no

significant differences were observed in RSNA responses to
SP in control SHR and WKY rats (figure 21).
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Figure 20: Typical changes in blood pressure, raw renal
sympathetic nerve activity (RSNA) and integrated RSNA in SHR
and WKY rats due to 30 nmol/kg substance P (SP).
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Figure 21: Change in renal sympathetic nerve activity 20
seconds after substance P injections in SHR and WKY rats.
Nerve activity is expressed in arbitrary units proportional to
(volts/sec) . No significant differences in the response are
exhibited.
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It is interesting to note that a similar inhibition of
RSNA is observed following injection of NE, which is likely
to be due to activation of baroreceptors (figure 22).

Since

only stimulatory effects of SP on RSNA are seen following
ganglion blockade (figure 23), renal nerve responses to SP
were evaluated following blockade of ganglion nicotinic
receptors with chlorisondamine (20 /mol/kg).
After ganglion blockade, SHR exhibited an enhanced RSNA
response to SP, but this was statistically significant at
only one dose (3 nmol/kg).

Differences in stimulation of

RSNA following injection of 10-30 nmol/kg SP in SHR and WKY
rats did not achieve statistical significance due to large
variability in the response (figure 24).

Excessive lowering

of basal blood pressure by chlorisondamine in some rats may
have caused a lack of responsiveness which contributed to
this variability.
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NE
IQ nm ol/kg

1 minute

Figure 22: A typical blood pressure, raw renal sympathetic
nerve activity (RSNA) and integrated RSNA response to 10
nmol/kg norepinephrine (NE).
„ SP
30 nmol/kg

1 minute

3 0 rvnol/kg

Ganglion
Blockade

1 minute

Figure 23: Typical blood pressure, raw renal sympathetic nerve
activity (RSNA) and integrated RSNA responses to 30 nmol/kg
substance P (SP) prior to (left panel) and following (right
panel) ganglion blockade with 20 pmol/kg chlorisondamine.
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Change in Renal Sympathetic Nerve Activity due to
Substance P after Ganglion Blockade in SHR and WKY rats
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Figure 24: Change in renal sympathetic nerve activity due to
substance P in SHR and WKY rats following ganglion blockade
with 20 /raol/kg chlorisondamine.

Baroreceptor Mediated Control of RSNA
Purina Ganglion Stimulation with PMPP
Blood pressure, heart rate and RSNA responses to DHPP
(0.03-1.0 ^mol/kg) were obtained in male CD rats (300-475g).
Dose-response curves for the increase in RSNA were
constructed in control (n=6), sinoaortic denervated (SAD,
n=5), pithed (n=5), and adrenoceptor blocked (n«5) groups.
All groups were paralyzed by injection of 50 jiraol/kg
gallamine triethiodide and artificially respired.
Ganglion stimulation by DMPP was found to have complex
effects on RSNA in control rats consisting of both
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stimulatory and inhibitory influences.

The elevation in

blood pressure caused by DMPP lead to baroreceptor
activation which reflexively decreased RSNA.

in contrast,

the direct effect of DHPP on ganglion nicotinic receptors is
to increase sympathetic tone.

At low doses of DMPP (£ 0.1

Mmol/kg) baroreceptor-induced inhibition of RSNA
predominated.

In many instances no increase in RSNA was

observed even though DHPP increased blood pressure (data not
shown).

Higher doses were characterized by a brief (2-5

second) but substantial increase in RSNA followed by longlasting inhibition of nerve activity (figure 25).
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Figure 25: Typical change in heart rate, blood pressure, raw
renal sympathetic nerve activity (RSNA) and integrated RSNA
following
injection
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0.56
^mol/kg
1,1-dimethyl-4phenylpiperazinium (DHPP) in a control (untreated) CD rat.
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The effect of DMPP to inhibit RSNA was eliminated
following SAD or destruction of the central nervous system
by pithing (figures 26,27), indicating that it is due to
activation of baroreceptors.

This idea is supported by

experiments employing the a-adrenoceptor antagonist
phenoxybenzamine (30

nmol/kg), in which the inhibitory

effect of baroreceptor activation was prevented by blocking
the effect of DMPP to increase arterial pressure.

Following

a-adrenoceptor blockade, DMPP exhibited a depressor effect
and the stimulatory action of DMPP on RSNA was enhanced and
prolonged (figure 28).

Propranolol (5 /mol/kg) was given to

a-adrenoceptor blocked rats to eliminate fi-adrenoceptor
mediated depressor effects of DMPP, which may also affect
RSNA.

Under these circumstances the initial DMPP induced

increase in RSNA was also enhanced but was followed by a
small increase in blood pressure and slight inhibition of
RSNA (figure 29).
No statistical differences were observed in the maximum
stimulation of RSNA by DMPP in SAD vs. adrenoceptor blocked
groups (data not shown).

Responses to 0.56 jxmol/kg DMPP

were significantly increased in SAD vs. control rats over
the entire time course of the response.

In addition,

baseline RSNA was significantly elevated by baroreceptor
denervation.

Responses of pithed animals to DMPP were

attenuated compared to control (figure 30).
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Figures 26 6 27: Typical changes in heart rate, blood
pressure, raw renal sympathetic nerve activity (RSNA) and
integrated RSNA following injection of 0.56 praol/kg 1 ,1 dimethyl-4-phenylpiperazinium
(DMPP)
in
baroreceptor
denervated (left panel) or pithed (right panel) CD rats.
Inhibitory effects of DMPP on RSNA are eliminated following
these procedures, although a transient decrease in RSNA is
sometimes observed in SAD rats immediately following the
stimulatory effect of DMPP.
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Figures 20 0 29: Typical changes in heart rate, blood
pressure, raw renal sympathetic nerve activity (RSNA) and
integrated RSNA following injection of 0.56 /mol/kg 1,1dimethyl-4-phenylpiperazinium (DMPP) in a CD rat after aadrenoceptor blockade with 30 /imol/kg phenoxybenzamine (left
panel) or combine a- and B-adrenoceptor blockade with
phenoxybenzamine (30 jmol/kg) and propranolol (5 /imol/kg).
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Time Course of Efferent Renal Nerve
Activity Following DMPP Injection
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Figure 30: Tine course of efferent renal nerve activity before
and
after
injection
of
0.56
/irool/kg 1, l-dimethyl-4phenylpiperazinium (DMPP) in control, pithed, and sinoaortic
denervated CD rats.

Effect of Adrenoceptor Blockade on
Blood Pressure Responses to Substance P
Blood pressure responses to SP (0.3-32 nmol/kg) were
measured in paralyzed, ventilated 10-12 week old male SHR
(n=5) and WKY (n=5) rats before and following adrenoceptor
blockade with phenoxybenzamine (10 /imol/kg) and propranolol
(5 jimol/kg).

Adrenoceptor blockade was employed to prevent

the effect of SP to increase blood pressure, thus allowing
for comparison of depressor responses to SP in SHR and WKY
rats.

Because SP is a less powerful pressor agent than
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DMPP, a lower concentration of phenoxybenzamine was
necessary here than was previously employed to block the
pressor effects of DMPP (10 versus 30 /unol/kg,
respectively).
Cardiovascular responses to SP prior to adrenoceptor
blockade were similar to those observed in previous studies
(figure 31), although some differences were observed (see
chapter 4, p.71).

Adrenoceptor blockade lowered mean

arterial pressure more in SHR than WKY rats (figure 32).
Pressor effects of SP were eliminated by a-adrenoceptor
blockade (figure 33).

Depressor effects of SP were also

attenuated, perhaps due to the lower baseline blood
pressures exhibited after adrenoceptor blockade.

Depressor

effects of SP were attenuated in SHR compared to WKY rats,
with the greatest difference being exhibited at the two
highest doses of SP.

This difference in response to high

doses of SP was not prevented by increasing the
concentration of phenoxybenzamine (data not shown).
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Change In MAP 20 sec Following Substance P
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Figure 31: The change in mean arterial pressure (MAP) 20
seconds after injection of substance P in SHR and WKY rats.
Blood pressure responses of SHR were significantly different
from WKY rats at all doses tested (p < 0.05, one-way ANOVA).
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Figure 32: Baseline mean arterial pressures in SHR and WKY
rats prior to and following adrenoceptor blockade with 10
pmol/kg phenoxybenzamine and 5 /jmol/kg propranolol.
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Figure 33: The change in mean arterial pressure (HAP) 20
seconds following injection of substance P in SHR and WKY rats
after adrenoceptor blockade with 10 /mol/kg phenoxybenzamine
and 5 pmol/kg propranolol.

Effect of Baroreceptor Denervation on
Cardiovascular and RSNA Responses to SP. DMPP and NE
Blood pressure, heart rate and RSNA responses were
measured following intravenous injection of SP (0.3-32
nmol/kg), DMPP (0.1-1.0 /mol/kg), and NE (0.3-32 nmol/kg) in
paralyzed, ventilated 10-13 week old male SHR and WKY rats.
Both baroreceptor-intact (SHR, WKY) and sinoaortic
denervated rats (SHR-d, WKY-d) were used.

SHR exhibited

greater intrinsic RSNA and less enhancement of RSNA
following SAD than WKY rats (figure 34).

In addition,

differences were observed in the character of nerve
recordings (figure 35).
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Figure 34: Total power o£ baseline renal sympathetic nerve
activity before and after sinoaortic denervation in SHR and
WKY rats.
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Figure 35: Typical renal nerve recordings from baroreceptorintact (SHR, WKY) and sinoaortic denervated (SHR-d, WKY-d)
rats.
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Prior

to

baroreceptor

denervation,

pulsatile

nerve

activity in SHR was greater both in magnitude and frequency
compared to WKY rats.
following

However, this difference was abolished

sad.

Denervation significantly enhanced responses to ganglion
stimulation by SP (figure 36) and DMPP (figure 37), although
no significant differences were seen between SHR and WKY or
SHR-d and WKY-d.

However, because RSNA varied greatly during

experiments, responses were more accurately represented when
expressed as a percent of the baseline RSNA immediately prior
to drug injection.

When measured in this manner, SHR-d did

exhibit an elevated RSNA response to high doses of SP when
compared to WKY-d (figure 38).

Similar differences were not

observed in the response to DMPP (figure 39).
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Figure 36: Maximum total power measured per second in renal
sympathetic nerve discharges before and following intravenous
injection of substance P in control SHR and WKY rats and
following baroreceptor denervation (SHR-d, WKY-d). Substance
P concentration is in mol/kg.
Denervation of baroreceptors
enhanced RSNA responses to 1.0-32 nmol/kg SP.
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Figure 37: Maximum total power measured per second in renal
sympathetic nerve discharges before and following intravenous
injection of l,l-dimethyl-4-phenylpiperazinium (DMPP)
in
control SHR and WKY rats and following baroreceptor
denervation (SHR-d, WKY-d), DMPP concentration is in mol/kg.
Denervation of baroreceptors enhanced RSNA responses to all
doses of DMPP.
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Percent Increase In Total Power of Renal Nerve
Activity Following Substance P Injection
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Figure 38: Percent increase in maximum total power of renal
sympathetic nerve discharges following substance P injection
in SHR and WHY rats.
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Figure 39: Percent increase in maximum total power of renal
sympathetic nerve discharges following injection of 1,1dimethyl-4-phenylpiperazinium in SHR and WKY rats.

Blood pressure responses to SP in control and
denervated SHR and WKY rats were comparable to those
obtained in previous studies (figure 31).

Compared to WKY

rats, SHR exhibited a slightly greater increase in pressure
due to DMPP (figure 40), but not to NE (figure 41).
rate responses were complex.

Heart

Although reflex bradycardia

was not seen following SAD, basal heart rate was frequently
increased and drug-induced increases in heart rate were
blunted.

Responses to SP were enhanced in control SHR

(figure 42).

No other differences were seen in heart rate

responses with the exception of a slight increase in the
response of SHR-d to DMPP (figure 43).

Increase In Mean Arterial Pressure Following
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Figure 40: Increase in mean arterial pressure observed
following injection of
l,l-dimethyl-4-phenylpiperazinium
(DMPP) in SHR and WKY rats.
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Increase in Arterial Pressure Following
Norepinephrine Injection in SHR and WKY rats
120
O i

i

100

□ SHR (n=5)
o WKY (n=6)

40

-9 5

-9.0
- 8.0
-8 5
Log [norepinephrine] (mol/kg)

-7 5

Figure 41: Increase in mean arterial pressure observed
following injection of norepinephrine in SHR and WKY rats.

Increase in Heart Rate Following Substance P
Injection in SHR and WKY rats
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Figure 42: Increase in heart rate observed following injection
of substance P in SHR and WKY rats.
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Increase in Heart Rate Following DMPP Injection
in Sinoaortic Denvervated SHR and WKY rats
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Figure 43: Increase in heart rate observed following injection
of 1,l-dimethyl-4-phenylpiperaziniwn (DMPP) in baroreceptor
denervated SHR and WKY rats.

CHAPTER 4
Discussion

The enhanced renal sympathetic responsiveness of SHR
versus WKY rats to SP observed in the current study
indicates that SP may be involved in the elevation in basal
and environmentally evoked sympathetic discharges observed
in this model of hypertension.

In addition, an attenuation

of the depressor effect of SP in SHR was observed which is
in agreement with previous studies (Virus et al., 1981).
The origin of these changes in cardiovascular and
sympathetic responsiveness to SP in SHR is not known.
However, it is possible that they are causally linked.
Studies have shown that sympathetic ganglia are
surrounded by a dense network of substance F-immunoreactive
fibers (Hokfelt et al., 1977).

These appear to be sensory

in origin, arising as collateral branches of primary sensory
neurons with terminations in the periphery (Baker et al.,
1980; Dalsgaard et al., 1982; Matthews and Cuello, 1982).
It has been proposed that in addition to sending information
to the dorsal spinal cord, stimulation of peripheral
terminals of primary sensory neurons may cause the release
of SP in sympathetic ganglia where it facilitates nicotinic
neurotransmission (Konishi and Otsuka, 1985).

This raises

the possibility that reflex modulation of sympathetic tone
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nay occur outside of the central nervous system.

Since the

heart and vasculature are densely innervated by both sensory
and sympathetic nerves, this reflex nay be important for
regulation of cardiovascular function (figure 44).

This

proposal is supported by two lines of evidence.
First, the release of substance P in sympathetic
ganglia appears to play an important role in modulation of
sympathetic tone.

Several studies have shown that SP has a

stimulatory effect in sympathetic ganglia (Otsuka and
Yoshioka, 1993).

For example, iontophoretic application of

SP to sympathetic postganglionic neurons produces a delayed
onset long lasting depolarization which is blocked by SP
antagonists (Konishi and otsuka, 1985).

This stimulatory

action of SP lowers the threshold for excitation of ganglion
neurons and can even initiate a burst of action potentials
(Tsunoo et al., 1982).
Secondly, modulation of sympathetic tone by SP probably
plays an important role in cardiovascular regulation.
Depletion of SP in the whole animal by neonatal treatment
with capsaicin reduces blood pressure and impairs reflex
compensation to hemorrhage or vasodilators (Donnerer and
Lembeck, 1989).

In contrast, intravenous injection of SP in

low nanomolar concentrations increases heart rate and blood
pressure (Hancock, 1992).

Thus, SP released from sensory

nerve terminals in sympathetic ganglia is likely to exert a
significant influence on the cardiovascular system and may
be necessary for the maintenance of normal sympathetic drive.
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Figure 44: The circuitry involved in substance P-mediated
modulation of neurotransmission in sympathetic ganglia. Sensory
neurons of the dorsal root ganglion with perivascular nerve
terminals give
off collateral
branches which
innervate
sympathetic ganglia.
Sensory stimuli in the vasculature may
potentially lead to the release of substance P (SP) in
sympathetic ganglia, where it facilitates neurotransmission.
Presynaptic modulation of SP and acetylcholine (ACh) release by
enkephalins (Enk) may also be involved (from Rand et al., 1990).
If modulation of sympathetic tone by SP in sympathetic
ganglia is important in peripheral regulation of the
cardiovascular system, then it is also possible that SP may be
involved in cardiovascular disorders.

Spontaneously

hypertensive rats were used in the current study to test the
proposal that changes in the peripheral action of SP to
increase sympathetic tone may contribute to the development of
hypertension.

Information from several studies supports this

idea, particularly in regard to the SHR model of hypertension.
For example, there is abundant evidence that sympathetic
overactivity contributes to development of hypertension in the
SHR (Ekas and Lokhandwala, 1981; Folkow, 1989; Magee and

Schofield, 1992; Palermo et al., 1981).

In addition, this

elevation in sympathetic tone is apt to be due in part to
changes in the sensitivity of sympathetic ganglia.

It has

been demonstrated that in SHR, superior cervical ganglion
neurons exhibit increased excitability to intracellular
stimulation (Yarowski et al., 1981).

Evidence that SP is

involved in this enhanced sensitivity is provided by recent
observations that superior cervical ganglia of SHR exhibit
elevated SP-immunoreactivity compared to ganglia of WKY
rats.

Gurusinghe and Bell (1989) have demonstrated that

compared to WKY rats, approximately 2-3 times as many
principal cells of superior cervical ganglia in SHR are
invested by SP-immunoreactive varicosities.

This was not

due simply to a greater number of ganglion cells since no
differences were observed in the total number of neurons.
Thus, these observations indicate that excessive sympathetic
drive in SHR may be generated in part at the ganglionic
level by greater actions of SP to increase excitability of
ganglion neurons and enhance nicotinic neurotransmission.
In the present study, dose-dependent increases in blood
pressure, heart rate, and renal sympathetic nerve activity
were observed following intravenous injection of SP in both
SHR and WKY rats.

These effects persisted following

ganglion blockade, pithing, and sinoaortic denervation,
suggesting that they are due to a direct action of SP to
stimulate postganglionic sympathetic nerve activity.

This

is in agreement with previous observations by Hancock (1992)
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on the effects of SP on blood pressure and heart rate In CD
rats.
Increases in blood pressure due to SP were consistently
much greater in SHR than in WKY rats, supporting the idea
that ganglion actions of SP are enhanced in SHR.

Some

differences were observed between different groups of SHR
and WKY rats (compare figures 17 and 31).

However, these

dissimilarities are probably due to the fact that artificial
respiration was employed in some sets of experiments (figure
31) but not in others (figure 17).

Artificially ventilated

rats are not subject to decreases in respiratory rate which
can occur following injection of SP.

This inhibition of

respiration probably also has effects on blood pressure.
However, it cannot account for differences in blood pressure
responses seen between SHR and WKY rats.
Differences in the blood pressure response to SP in SHR
and WKY rats did not appear to be caused by generalized
changes in sensitivity to ganglion stimulation since pressor
responses to DMPP in the two groups were similar.

In

addition, the pressor effects of NE were nearly identical in
SHR and WKY rats, suggesting that differences in the effects
of SP on arterial pressure were not due to enhanced aadrenoceptor responsiveness of SHR.

However, since SP also

transiently decreased blood pressure, it is possible that
this influenced measurement of increases in blood pressure.
This idea is discussed in more detail below.
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It should be noted here that an Increased vascular
responsiveness to catecholamines has been reported in SHR
(Sun and Hanig, 1983; Folkow, 1986}, which is exaggerated by
cardiovascular hypertrophy occurring in older SHR.

The use

of young adult SHR and WKY rats (9-13 weeks of age) in the
current study may explain this lack of increase in
vasoconstriction to norepinephrine.
As in the case of the blood pressure response,
tachycardic effects of SP were greatly exaggerated in SHR
compared to WKY rats, consistent with an increased action of
SP in SHR to enhance sympathetic drive to the heart.
However, a slight enhancement in the tachycardic response to
DMPP was also observed.

Because DMPP increases blood

pressure markedly and thereby activates arterial
baroreceptors, differences in heart rate responses to DMPP
could conceivably be explained by attenuation of baroreflex
control of heart rate in the SHR.

This idea is supported by

previous studies (Harada et al., 1992}.

This is not the

case, however, since differences were exhibited both in
control and in baroreceptor denervated rats.

Since both SP

and nicotinic stimulants can stimulate epinephrine release
from adrenal chromaffin cells (Zhou and Livett, 1990}, and
previous studies have shown that much of the tachycardic
effect of SP results from adrenomedullary stimulation
(Hancock, 1992), it is possible that sensitivity of the
adrenals is non-specifically enhanced in SHR and this may
account for the increased tachycardic response to DMPP.
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This idea could be tested by comparing heart rate responses
to DMPP in SHR and WKY rats before and after bilateral
adrenalectomy.

The sensitivity of flj^-adrenoceptors did not

appear to be altered in SHR since tachycardic effects of NE
in SHR and WKY rats were not different.
Substance P also decreased blood pressure more in WKY
rats than SHR, an action which precedes its effect to
increase blood pressure.

This depressor action of SP is

believed to be mediated by NKx receptors located on
endothelial cells (Otsuka and Yoshioka, 1993; Regoli et al.,
1990) which release endothelium-derived relaxing factor
(EDRF).

Endogenous activation of these receptors is thought

to occur via an axon reflex mechanism resulting in the
release of SP from sensory terminals in the vasculature.
The effect of SP to decrease arterial pressure more in WKY
rats than SHR is not surprising since blunting of
endothelium-dependent vasodilatory responses in SHR has been
noted in several studies (Luscher et al., 1992).

In

addition, attenuation of depressor responses to SP in SHR
has previously been observed (Virus et al., 1981; Pompei et
al., 1993) and attributed to a decrease in endothelial cell
mediated vasodilation.
Attenuation of SP-induced vasodilation probably
contributes to the elevation in arterial pressure above
baseline observed in SHR following high doses of SP.

This

is likely since vasodilatory effects of SP directly
antagonize the constrictor influences of neurally released
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norepinephrine on vascular smooth muscle cells.

If

antagonism of vasoconstriction by SP is less in SHR, this
would lead to greater increases in arterial pressure
following stimulation of sympathetic ganglia.
Ganglion blockade with 20 pmol/kg chlorisondamine
greatly decreased baseline RSNA in both SHR and WKY rats,
though comparatively less so in WKY rats than SHR.

It

should be noted here that nerve activity following ganglion
blockade contained spiking activity which was significantly
above the level of background noise, as evaluated 12 hours
after death.

This is in conflict with the common practice

in some studies of setting background noise levels to those
observed after ganglion blockade.

The meaning of this

residual activity is somewhat ambiguous since the origin of
potentials remaining after ganglion blockade is unclear.

An

obvious but unproven hypothesis is that they are generated
by the stimulant action of a noncholinergic transmitter,
perhaps substance P.
Following injection of SP in SHR and WKY rats, renal
nerve discharges exhibit a gradual increase in frequency and
amplitude.

This coincides with the increase in blood

pressure, supporting the proposition that they are causally
linked.

Both responses reached a maximum after about 20

seconds, then decayed slowly over the next minute.

Although

blood pressure responses to SP in SHR and WKY rats were
considerably different, no differences were seen in the
effect of SP on RSNA in control SHR and WKY rats.

This can
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best be explained by the fact that renal nerve activity is
consistently and profoundly influenced by the magnitude of
baroreceptor discharge.

Since SP affects mean arterial

pressure and thus baroreceptor activity, RSNA responses to
SP in control rats are presumably "baroreceptor biased".
The finding that baroreceptor activation precludes
direct measurement of RSNA responses to SP prompted the
testing of several techniques to eliminate baroreceptor
input.

Following ganglion blockade with 20 /mol/kg

chlorisondamine, RSNA responses to SP were slightly greater
in SHR than WKY rats.

However, owing to high variability in

the response this was statistically significant at only one
dose.

It is likely that this is due to excessive lowering

of blood pressure following ganglion blockade, resulting in
deterioration of the preparation.

Subsequent experiments

demonstrated that blood pressures were better maintained
when rats were artificially ventilated.
CD rats were subsequently used to evaluate various
other treatments designed to eliminate baroreceptor input
during ganglion stimulation.

In these experiments the

ganglion stimulant DMPP was used owing to the fact that in
control rats, RSNA responses to DMPP demonstrated marked
baroreceptor-mediated inhibition.

The response involves a

brief (2-5 sec) but intense burst of activity followed by a
long-lasting (1-2 min) inhibition of RSNA.

The inhibitory

response was confirmed to be baroreceptor mediated since it
was eliminated following sinoaortic denervation or pithing,
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or by a-adrenoceptor blockade with 30 jimol/kg
phenoxybenzamine.

After evaluation of the various

techniques for eliminating baroreceptor input, sinoaortic
denervation was chosen on the basis of its effectiveness and
selectivity.
Cardiovascular effects of DMPP after adrenoceptor
blockade were complex.

Pressor and tachycardic effects of

DMPP were attenuated but not eliminated by blockade of both
a- and B-adrenoceptors with phenoxybenzamine and
propranolol.

The pressor effect of DMPP remaining after

adrenoceptor blockade may be due to increased cardiac
output.

Another possibility is that ganglion stimulation

causes the release of a nonadrenergic vasoconstrictor whose
pressor effect is revealed only after blockade of vascular
B2~adrenoceptors.

Since sympathetic cardiovascular

terminals are particularly rich in the vasoconstrictor
neuropeptide Y (NPY) (Lundberg et al., 1982), this peptide
may participate in the pressor response observed following
ganglion stimulation.

Agonist/antagonist competition at

cardiac B-adrenoceptors may explain the tachycardia
produced by DMPP after 5

ol/kg propranolol.

It should be noted that since the increase in blood
pressure caused by DMPP was sustained even though RSNA was
decreased, changes in renal nerve activity produced by
ganglion stimulants are not always accompanied by
corresponding changes in blood pressure.

This may be

explained by overflow of neurally-released catecholamines
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into the plasma.

In fact, sympathetic activity is often

evaluated by measuring changes in the level of plasma
catecholamines.

Since blood pressure was also maintained

above baseline for 1-2 minutes following NE injection (see
figure 16), a sustained increase in plasma epinephrine
and/or norepinephrine probably accounts for the long-lasting
elevation in blood pressure following injection of DMPP.

In

this way, blood pressure may remain elevated after ganglion
stimulation has ceased.
Prior to sinoaortic denervation, renal nerve discharges
in SHE were greater in both frequency and amplitude compared
to WKY rats, consistent with the literature (Ekas and
Lokhandwala, 1981).

This elevation of intrinsic RSNA in SHR

is best described as a change in the pattern and size of
bursts of nerve activity.

Discharges of renal sympathetic

nerves were synchronized with pulse pressure in both SHR and
WKY rats, with "bursts” of activity occurring most often
during diastole.

The frequency of these bursts was greater

in SHR due to their occurrence during a greater percentage
of cardiac cycles.

Nerve recordings from SHR exhibited

action potentials during diastole in 80-90% of cardiac
cycles, sometimes continuing to fire over the course of 2-3
cycles.

In contrast, recordings from WKY rats often

displayed bursts during only about 50% of cardiac cycles.
In addition, peak nerve discharges were usually slightly
larger (about 200 pV) in SHR compared to WKY rats (about 150
/iV).

This difference between the pattern of discharge in

renal nerve recordings from SHR and WKY rats may be due to
an attenuation of baroreceptor-mediated inhibition of RSNA
in SHR, indicated by the fact that sinoaortic denervation
enhanced intrinsic RSNA more in WKY than SHR by eliminating
pulse-synchronous activity.

Following sinoaortic

denervation renal nerve recordings from both SHR and WKY
rats exhibited continuous asynchronous discharge.

These

types of differences in pre- and post-denervation nerve
activity are in agreement with electrophysiological evidence
that tonic discharge of arterial baroreceptors is decreased
in SHR (Brown et al., 1976).
As in the case of responses to DMPP, increases in RSNA
following injection of SP were profoundly enhanced by
sinoaortic denervation, confirming suspicions that
baroreceptor influences on renal nerve activity during
ganglion stimulation by SP are significant.

Baroreceptor

denervated SHR exhibited an elevated RSNA response to SP
compared to WKY rats when nerve activity is expressed as a
percent of the pre-drug baseline.

This same increase was

not observed for RSNA responses to DMPP, indicating that a
selective enhancement of ganglion sensitivity to SP occurs
in the SHR.

in light of these data, it seems likely that

differences in the ability of SP to increase blood pressure
in SHR and WKY rats are due to a combination of two factors.
As previously noted, SP causes less vasodilation in SHR than
WKY rats, allowing for a greater effect of vasoconstrictor
influences.

In addition, a greater sympathetic discharge to
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the vasculature occurs In SHR compared to WKY rats after
injection of SP resulting in greater a-adrenoceptor
stimulation and thus enhanced vasoconstriction.

The

combination of these two factors is probably responsible for
the consistent differences observed in blood pressure
responses to SP in SHR and WKY rats.
The results of this study demonstrate that in SHR there
is an increase in basal and evoked sympathetic tone.
Elevation in basal sympathetic tone may be due to decreased
baroreceptor-mediated inhibition of sympathetic outflow in
SHR.

This is indicated by observations that denervation of

baroreceptors enhanced sympathetic tone more in WKY rats
than in SHR.

In addition, discharges in renal nerves which

persisted after ganglion blockade were observed.

These

potentials are presumed to be generated peripherally, and
may be due to release of SP in sympathetic ganglia,

since

this residual activity was greater in SHR than WKY rats, it
is possible that an increased action of SP may also
contribute to elevations in basal sympathetic outflow in
SHR.
A selective increase in renal nerve responses to
ganglion stimulation by substance P was observed.

This was

not also observed in response to ganglion nicotinic receptor
stimulation by DMPP.

Thus, SP may be responsible, at least

in part, for the increased excitability of sympathetic
ganglia in SHR.

This effect of SP may in turn play a role

in the increase in evoked sympathetic responses in SHR.
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It is unknown why the sympathostimulatory effects of SP
are enhanced in SHR.

One possibility is that it is merely a

hereditary trait of SHR.

Genetic programming may result in

a different pattern of sensory innervation in sympathetic
ganglia of SHR versus WKY rats.

However, if peripheral

modulation of sympathetic tone by SP is subject to reflex
control by activation of sensory nerve terminals in the
vasculature, then vascular alterations may disrupt this
reflex.

Thus, there may be a connection between the

observed decrease in vasodilator effect and enhanced
sympathetic responses to SP in SHR.
In conclusion, it appears that a selective increase in
the action of SP to enhance neurotransmission in sympathetic
ganglia is exhibited in SHR compared to WKY rats which may
contribute to an elevation in basal and evoked sympathetic
tone.

This may result from changes in the vasculature which

affect sensory regulation of vasomotor tone and contribute
to elevations in blood pressure.

Future studies utilizing

non-genetic models of hypertension may help to increase
understanding of the precise role that SP plays in the
development of hypertension.

Measurements of cardiovascular

and sympathetic responses to substance P in models of
hypertension such as the DOCA-salt (deoxycorticosterone
acetate) rat may provide a clue as to whether or not changes
in responsiveness to SP observed in SHR are genetically
programmed or are the result of physiological adaptations to
high blood pressure.

CHAPTER 5
Summary

Results of the present study demonstrated the following:
1.

Following intravenous injection of substance P, SHR
exhibit a dose-dependent increase in blood

pressure and

heart rate which is significantly greater than that
observed in normotensive WKY rats.
2.

Increases in blood pressure and heart rate
substance P are accompanied by an increase

due to
in renal

sympathetic nerve activity (RSNA) which persists after
ganglion blockade or pithing.
3.

Baroreceptor mediated inhibition of RSNA significantly
depresses responses to sympathetic ganglion stimulation
by both substance P and the nicotinic agonist DMPP.

4.

SHR exhibit greater intrinsic sympathetic tone and less
enhancement of RSNA following baroreceptor denervation
than WKY rats.

5.

After adrenoceptor blockade, only depressor responses
to substance P are exhibited.

These responses are

attenuated in SHR compared to WKY rats.
6.

After sinoaortic denervation, SHR exhibit an enhanced
RSNA response to ganglion stimulation by substance P
versus WKY rats.

7.

Enhanced cardiovascular and sympathetic responses to
substance P in SHR rats are not the result of
generalized increases in ganglion or adrenoceptor
sensitivity.
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